With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacific Rim countries.
ASIA by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
Melbourn Scientific Opens EU Market with Inhaler Test Service
formulation for inhaled products, the company is now said to offer one of largest teams in Europe offering contract research for OINDP development, product development and associated CMC services. These include formulation development, analysis, stability studies, inhaler testing and small scale manufacture of clinical trials materials.
Melbourn Scientific has been audited by the MRHA and FDA and was recently awarded a Manufacturer's/Importer’s Authorisation (MIA) allowing it to be named as an EU testing and release site.
CEO Mark Hammond said the new licence is a good endorsement of the quality of the company’s cGMP procedures and extends its capabilities: “The EU is an important market and with the Manufacturer’s / Importer’s Authorisation (MIA), we are able to import commercial products which have been manufactured outside the EU and to test them prior to release for sale within the EU/EEA. This has extended our portfolio of services for international clients.
Mark Hammond
Import testing for companies wanting to access European markets is just one of the services being offered by Melbourn Scientific at Inhalation Asia, Hong Kong (26-28 June).
With over 20 years of experience in analytical testing and
Hammond continued “We are seeing an increase in interest from companies across Asia and India who are looking for CRO partners with proven expertise in supporting inhaled and intranasal programs. Inhalation Asia will be the first time we have exhibited in the Far East and we are looking forward to the experience."
More Info. 162 Horizon Discovery Establish Genetic Research Centres in Asia
Horizon Discovery a leading provider of research tools to support the development of personalised medicines has established three new Centers of Excellence (CoE’s) for gene editing in Asia. The new Centers at Aichi Cancer Center, Japan, Seoul National University, South Korea, and the National Cancer Centre (NCC), Singapore will use Horizon‘s GENESIS gene engineering technology to generate human isogenic cell lines harboring specific genes/mutations relating to cancer.
The Aichi Cancer Center is Horizon’s third CoE in Japan, and will focus on elucidation of the molecular mechanisms of viral proliferation and oncogenesis of Epstein Barr Virus, as part of the world-wide effort to combat virally-initiated cancers. The PI for this program will be Takayuki Murata.
Seoul National University, Institute of Molecular Biology and
Genetics, will work with Horizon to create isogenic cell lines to study the regulatory mechanisms of BubR1 spindle assembly checkpoint, in order to increase understanding of the basis of genetic instability of cancer. Associate Professor Hyunsook Lee will be leading the program for Seoul National University.
Dr Daniel SW Tan, PI at the NCC Singapore, Department of Medical Oncology, will use Horizon’s technology to study the effects on cell lines of cancer-causing EGFR mutations, which are implicated in a wide range of cancer types.
“We are delighted these three new institutes have joined our Centers of Excellence program,” said Dr Rob Howes, Principal Scientist, Horizon. “We are excited to continue expanding our rAAV genome editing network into Asia, and hope to add to this further through 2013."
Nottingham-Australia Collaboration on Future Environmental Planning
The national parks, nature reserves and wetlands of the semi-arid wheatbelt of Western Australia with their rich diversity of flora and fauna are the backdrop for new research to improve the management of natural resources in the 21st century.
The project will combine the latest ideas in computer science at The University of Nottingham with the pioneering ambitions of forward-thinking Australian environmental planners.
Researchers from the University’s Horizon Digital Economy Research Institute are working with the Western Australian Department of Environment and Conservation (DEC) to create new software tools and processes to create a new environmental planning framework called Value-Plan.
Specifically, the goal of the research project is to acquire accurate information on the values people like farmers, industry professionals and conservationists attach to a wide variety of
biological assets in Australia and incorporate this into a new environmental planning approach.
The new survey tools and intelligent data software to be researched and developed will inform decision-making at government level in the field of sustainable development and environmental policy planning. It is hoped the approach will ultimately be adopted by government and non-government organisations alike, and could be applicable to a diverse range of management applications, including town planning and natural resource management.
The system will be trialled over the next two years in two conservation areas of Western Australia, and initial work has already begun at the Lake Warden Natural Diversity Recovery Catchment near Esperance.
BioAlliance Pharma Pursues Drug Trial Through Japanese Partner Sosei
BioAlliance Pharma SA, a developer of orphan oncology products and supportive care products has announced the initiation of Loramyc®
/Oravig® Phase III clinical trial for the
treatment of oropharyngeal candidiasis by its Japanese partner Sosei. This is the final step before registration of the drug by Japanese authorities. In May 2011, BioAlliance Pharma signed a licensing agreement with Sosei Co Ltd for the conduct of development programme and commercialisation rights in Japan for Loramyc®
/Oravig® adhesive buccal tablet.
As traditionally required by Japanese authorities, a complementary development plan driven by Sosei has been initiated to complete the registration dossier and meet Japanese regulatory requirements. Following the successful phase I clinical trial finalised in July 2012, Sosei is now starting the final step of development with the phase III open-label, randomised trial versus miconazole gel. This study is anticipated to last 12 to 18 months.
"Loramyc® /Oravig® represents a true innovation in the
treatment of oropharyngeal candidiasis as compared with available treatments and is expected to improve patients' compliance and quality of life", commented Shinichi Tamura, CEO of Sosei Group Corporation. "The initiation of this phase III trial is a key step for us, not only in the development plan of the product in Japan but also in our discussions with potential partners for commercialisation once the product is approved."
"We are very pleased with this new step taken by our partner Sosei in Japan, which should lead them to the final stage of registration in the coming months. From there, commercialisation of Loramyc®
should then start in one of
the major Asian markets that is Japan", added Judith Greciet, CEO of BioAlliance Pharma.
More Info. 165 More Info. 163
BGI Health Seeks Local Business Partners within European Countries
BGI Clinical Laboratories, a medical diagnostics centre of BGI is seeking partners in European countries. BGI was founded in 1999 as a member of the International Human Genome Project and in recent years has become one of the largest genomic institutes of the world.
It offers a large range of genomics services in over 100 countries through the huge scientific networking. It has also published over 80 scientific papers in top science journals.
Further details visit
www.bgieurope.org More Info. 166 (miconazole Lauriad® ) muco-
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
More Info. 164
Contact us today for more information:
info@intlabmate.com
Business
Opportunities
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
